艾迪藥業(688488.SH):擬解除關於抗腫瘤在研藥物ACC006項目的權益轉讓事項
格隆匯12月26日丨艾迪藥業(688488.SH)公佈,公司及全資子公司南京安賽萊醫藥科技有限公司與廣州力鑫生物科技有限公司經友好協商,將解除關於抗腫瘤在研藥物ACC006項目的權益轉讓事項。
經雙方友好協商,由於出現協議雙方未能預見的事項,公司將與力鑫生物簽署《技術轉讓合同終止協議》。終止協議簽訂之日起,原《技術轉讓合同書》約定的權利義務終止,不再履行;公司將向力鑫生物退還其已支付的第一筆技術轉讓費人民幣3,000萬元,力鑫生物相應歸還公司提供的ACC006項目相關的全部資料,並辦理相關專利權屬的轉回手續;終止協議約定,原合同生效後,力鑫生物繼續開展ACC006項目臨牀研究所產生的所有費用均由力鑫生物自行承擔,豁免公司按照原協議約定應當承擔的50%研發費用和其他一切費用。
因本次轉讓尚未完成原合同約定的臨牀試驗申辦方變更,且項目後續能否申報NDA並取得《藥品註冊證書》存在較大不確定性導致交易價格存在可變對價,所以根據原合同約定及企業會計準則規定,公司尚未將3,000萬元確認為當期收入,因此款項退回不會對公司當期收益產生影響。
本次項目終止合作不涉及關聯交易,不涉及募投項目,不會影響公司的發展戰略和經營規劃,也不會對公司生產經營及財務狀況產生重大影響,不存在損害公司及廣大股東利益的情形;公司將圍繞HIV核心業務就ACC006繼續開展治療真菌感染方面的研發工作。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.